Market Place
Sourcing Support
BioCardia Reports Q3 2024 Business Highlights & Financial Results
13 Nov 2024 //
GLOBENEWSWIRE
BioCardia to Host Q3 2024 Corporate Update & Financial Results
06 Nov 2024 //
GLOBENEWSWIRE
BioCardia Completes Ph III Trial of Cell Therapy for Heart Failure
28 Oct 2024 //
#N/A
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
18 Sep 2024 //
GLOBENEWSWIRE
BioCardia Announces Closes $7.2 Million Public Offering
09 Sep 2024 //
GLOBENEWSWIRE
BioCardia Announces Pricing Of Upsized $7.2M Public Offering
30 Aug 2024 //
GLOBENEWSWIRE
BioCardia Receives FDA Clearance for Morph® DNA™ Steerable Introducer Product
29 Aug 2024 //
GLOBENEWSWIRE
FDA Approves CardiAMP Heart Failure II Protocol Amendment
21 Aug 2024 //
GLOBENEWSWIRE
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
BioCardia To Host Q2 2024 Update And Results Call On August 13
07 Aug 2024 //
GLOBENEWSWIRE
BioCardia Submits Morph® DNA™ Introducer For FDA Approval
30 Jul 2024 //
GLOBENEWSWIRE
Patient Enrollment Begins In CardiAMP Cell Therapy Phase 3 Trial
25 Jul 2024 //
GLOBENEWSWIRE
BioCardia Patents Morph DNA Catheter For Transseptal Use
17 Jul 2024 //
GLOBENEWSWIRE
CellProthera and BioCardia Collaborate on Phase II Trial of ProtheraCytes
08 Jul 2024 //
GLOBENEWSWIRE
BioCardia Gets US Patent For Heart Delivery Of Cell Aggregates
07 Jun 2024 //
GLOBENEWSWIRE
BioCardia Announces Reverse Stock Split
21 May 2024 //
GLOBENEWSWIRE
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
14 May 2024 //
GLOBENEWSWIRE
BioCardia Q1 2024 Call On May 14
09 May 2024 //
GLOBENEWSWIRE
BioCardia: CardiAMP Benefits In Chronic Ischemia Trial Outcomes
01 May 2024 //
GLOBENEWSWIRE
BioCardia Completes CardiAMP Cell Therapy Enrollment
25 Apr 2024 //
GLOBENEWSWIRE
BioCardia Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
BioCardia to Host 2023 Financial Results and Corporate Update 2024
20 Mar 2024 //
GLOBENEWSWIRE
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 Mar 2024 //
GLOBENEWSWIRE
BioCardia Announces Coverage for Cell Therapy Phase III Heart Failure Study
12 Mar 2024 //
GLOBENEWSWIRE
BioCardia Reports Results from PIII CardiAMP Cell Therapy Heart Failure Trial
04 Mar 2024 //
GLOBENEWSWIRE
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Study
08 Feb 2024 //
GLOBENEWSWIRE
BioCardia Announces Two Scientific Abstracts Have Been Accepted at Conference
31 Jan 2024 //
GLOBENEWSWIRE
BioCardia Morph Access Innovations Development Update for Shareholders
03 Jan 2024 //
GLOBENEWSWIRE
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03
19 Dec 2023 //
GLOBENEWSWIRE
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline
18 Dec 2023 //
GLOBENEWSWIRE
BioCardia Shares Update from PMDA Consultation on CardiAMP Cell Therapy
29 Nov 2023 //
GLOBENEWSWIRE
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock
16 Nov 2023 //
GLOBENEWSWIRE
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol
14 Nov 2023 //
GLOBENEWSWIRE
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference
01 Nov 2023 //
GLOBENEWSWIRE
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial
11 Oct 2023 //
GLOBENEWSWIRE
BioCardia Announces Next Steps on its Autologous CardiAMP Cell Therapy Programs
06 Sep 2023 //
GLOBENEWSWIRE
BioCardia Announces Results in PIII CardiAMP Cell Therapy Heart Failure Trial
05 Sep 2023 //
PRESS RELEASE
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
BioCardia to Host Q2 2023 Financial Results Conference Call on August 9, 2023
02 Aug 2023 //
GLOBENEWSWIRE
BioCardia pauses enrollment in PhIII trial of heart failure stem cell therapy
24 Jul 2023 //
ENDPTS
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure
05 Jul 2023 //
GLOBENEWSWIRE
BioCardia Announces FDA Completes Review Proposed Adaptive Statistical Analysis
20 Jun 2023 //
GLOBENEWSWIRE
BioCardia Announces Helix„¢ Biotherapeutic Delivery Patent Issuance in Japan
08 Jun 2023 //
GLOBENEWSWIRE
BioCardia Announces Timing of Board Meeting for the CardiAMP Cell Therapy
23 May 2023 //
GLOBENEWSWIRE
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
10 May 2023 //
GLOBENEWSWIRE
BioCardia Announces US Patent on Bone Marrow Derived (NK1R+) Mesenchymal SC
09 May 2023 //
GLOBENEWSWIRE
BioCardia to Host Q1 2023FYR & Corporate Update Conference Call
03 May 2023 //
GLOBENEWSWIRE
BioCardia Announces Issuance of Two Patents Related to Technology
04 Apr 2023 //
GLOBENEWSWIRE
BioCardia Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
BioCardia to Host 2022 Financial Results Conference Call on March 29, 2023
16 Mar 2023 //
GLOBENEWSWIRE
Positive Echocardiography Data from BioCardia PIII Trial Presented at Meeting
06 Mar 2023 //
GLOBENEWSWIRE
BioCardia & CellProthera Enhance Collaboration for Development of ProtheraCytes
01 Feb 2023 //
GLOBENEWSWIRE
BioCardia Letter to Shareholders
22 Dec 2022 //
GLOBENEWSWIRE
BioCardia Announces $3.6 Million Private Placement of Common Stock
15 Dec 2022 //
GLOBENEWSWIRE
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+
06 Dec 2022 //
BUSINESSWIRE
BioCardia off-the-shelf cell therapy to enter phase 1/2 study
06 Dec 2022 //
FIERCEBIOTECH
BioCardia to Host Q3 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial
03 Oct 2022 //
GLOBENEWSWIRE
CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data
14 Sep 2022 //
GLOBENEWSWIRE
